ERBB2 and cholangiocarcinoma: HSP90 inhibition is attractive in CCA because HSP90 interacts with and controls a variety of client proteins that play a key role in CCA pathogenesis, such as EGFR, PTEN, PI3K, HER2, HER3, and PRKA.